Prostate Cancer Diagnosis: the promise of urine biomarkers

Background: Prostate Cancer (PCa) is the second most common malignancy in UK with highly heterogenous presentation and outcomes. Its heterogeneity poses a significant diagnostic challenge in accurate PCa evaluation. Particularly, as current biomarker, prostate specific antigen (PSA), is not specific or sensitive enough. Nonetheless, non-invasive urine biomarkers seem to have addressed this dilemma and this poster aims to assess their credibility.